newsfilter
← Latest News
Business Wire·

OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit

Company to ring Closing Bell at NYSE on Thursday, October 3, 2024 Interviews scheduled with Fintech.TV and Schwab Network OS Therapies (NYSE:OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and